Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SYF2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SYF2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SYF2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SYF2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SYF2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SYF2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SYF2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SYF2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SYF2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SYF2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000039834 | Thyroid | ATC | mRNA splicing, via spliceosome | 197/6293 | 320/18723 | 6.54e-25 | 2.18e-22 | 197 |
GO:004477219 | Thyroid | ATC | mitotic cell cycle phase transition | 223/6293 | 424/18723 | 3.46e-16 | 2.88e-14 | 223 |
GO:000734622 | Thyroid | ATC | regulation of mitotic cell cycle | 236/6293 | 457/18723 | 7.58e-16 | 5.92e-14 | 236 |
GO:190199015 | Thyroid | ATC | regulation of mitotic cell cycle phase transition | 156/6293 | 299/18723 | 2.19e-11 | 7.80e-10 | 156 |
GO:000170126 | Thyroid | ATC | in utero embryonic development | 183/6293 | 367/18723 | 6.62e-11 | 2.11e-09 | 183 |
GO:190198715 | Thyroid | ATC | regulation of cell cycle phase transition | 187/6293 | 390/18723 | 2.36e-09 | 5.61e-08 | 187 |
GO:004578614 | Thyroid | ATC | negative regulation of cell cycle | 181/6293 | 385/18723 | 2.64e-08 | 5.07e-07 | 181 |
GO:190199115 | Thyroid | ATC | negative regulation of mitotic cell cycle phase transition | 94/6293 | 179/18723 | 1.33e-07 | 2.19e-06 | 94 |
GO:004593015 | Thyroid | ATC | negative regulation of mitotic cell cycle | 117/6293 | 235/18723 | 1.93e-07 | 3.05e-06 | 117 |
GO:004277016 | Thyroid | ATC | signal transduction in response to DNA damage | 90/6293 | 172/18723 | 3.01e-07 | 4.52e-06 | 90 |
GO:000709312 | Thyroid | ATC | mitotic cell cycle checkpoint | 69/6293 | 129/18723 | 2.52e-06 | 2.96e-05 | 69 |
GO:000008612 | Thyroid | ATC | G2/M transition of mitotic cell cycle | 72/6293 | 137/18723 | 3.61e-06 | 4.03e-05 | 72 |
GO:000007513 | Thyroid | ATC | cell cycle checkpoint | 84/6293 | 169/18723 | 1.05e-05 | 1.04e-04 | 84 |
GO:001094813 | Thyroid | ATC | negative regulation of cell cycle process | 134/6293 | 294/18723 | 1.19e-05 | 1.15e-04 | 134 |
GO:004483912 | Thyroid | ATC | cell cycle G2/M phase transition | 75/6293 | 148/18723 | 1.28e-05 | 1.24e-04 | 75 |
GO:190198813 | Thyroid | ATC | negative regulation of cell cycle phase transition | 116/6293 | 249/18723 | 1.33e-05 | 1.27e-04 | 116 |
GO:000736915 | Thyroid | ATC | gastrulation | 90/6293 | 185/18723 | 1.54e-05 | 1.43e-04 | 90 |
GO:001038911 | Thyroid | ATC | regulation of G2/M transition of mitotic cell cycle | 49/6293 | 94/18723 | 1.60e-04 | 1.10e-03 | 49 |
GO:190274911 | Thyroid | ATC | regulation of cell cycle G2/M phase transition | 51/6293 | 102/18723 | 4.45e-04 | 2.64e-03 | 51 |
GO:000709511 | Thyroid | ATC | mitotic G2 DNA damage checkpoint | 21/6293 | 34/18723 | 7.12e-04 | 4.00e-03 | 21 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SYF2 | SNV | Missense_Mutation | novel | c.104N>A | p.Arg35His | p.R35H | O95926 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-A2-A3KD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
SYF2 | SNV | Missense_Mutation | novel | c.212A>C | p.Lys71Thr | p.K71T | O95926 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYF2 | insertion | In_Frame_Ins | novel | c.611_612insGGGCCGGAGGTTCTCCTTGGCTTTTTGCTGGAACAGAAGCAG | p.Asp204delinsGluGlyArgArgPheSerLeuAlaPheCysTrpAsnArgSerSer | p.D204delinsEGRRFSLAFCWNRSS | O95926 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
SYF2 | deletion | Frame_Shift_Del | novel | c.509delG | p.Gly170GlufsTer15 | p.G170Efs*15 | O95926 | protein_coding | | | TCGA-D8-A3Z5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SYF2 | deletion | Frame_Shift_Del | novel | c.492delC | p.Asn165IlefsTer20 | p.N165Ifs*20 | O95926 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
SYF2 | SNV | Missense_Mutation | rs749059576 | c.505N>T | p.His169Tyr | p.H169Y | O95926 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-EK-A2R7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SYF2 | SNV | Missense_Mutation | novel | c.28N>A | p.Leu10Met | p.L10M | O95926 | protein_coding | tolerated_low_confidence(0.13) | benign(0.027) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SYF2 | SNV | Missense_Mutation | | c.675N>A | p.Phe225Leu | p.F225L | O95926 | protein_coding | deleterious(0.01) | possibly_damaging(0.846) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
SYF2 | SNV | Missense_Mutation | rs771119272 | c.701A>G | p.Lys234Arg | p.K234R | O95926 | protein_coding | deleterious(0.02) | probably_damaging(0.958) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SYF2 | SNV | Missense_Mutation | | c.288N>T | p.Glu96Asp | p.E96D | O95926 | protein_coding | tolerated(0.64) | benign(0.015) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |